Chemically Defined Media for Pancreatic Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human pluripotent stem cells into pancreatic progenitor and endocrine cells are inefficient, often requiring undefined animal products and resulting in heterogeneous populations, which can lead to teratoma formation and are limited to only a few cell lines, hindering their broad application in regenerative medicine and disease modeling.
Innovation Solution
A four-step process using chemically defined media with specific growth factors and inhibitors, such as TGFβ ligands, FGF, BMP, PI3K inhibitors, activin antagonists, and hedgehog signaling inhibitors, to differentiate pluripotent cells into pancreatic progenitor and endocrine cells, avoiding the use of animal-derived components and promoting homogeneity and safety for clinical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If undefined animal products (feeders, FBS, Matrigel) are used in culture media, then cell differentiation efficiency is improved, but manufacturing precision and homogeneity of cell populations deteriorate
Solution Approach 1:
The invention changes the chemical composition parameters of the culture media by replacing undefined animal products with precisely defined synthetic components. The chemically defined media contain specific concentrations of growth factors (TGFβ, FGF, BMP), inhibitors (PI3K inhibitor, GSK3β inhibitor), and other supplements with exact formulations, eliminating the variability inherent in animal-derived products while maintaining differentiation efficiency.
2Productivity
If undefined animal products are used in culture media, then cell differentiation efficiency is improved, but safety and risk of teratoma formation worsen
Solution Approach 1:
The invention changes the safety parameters by eliminating animal-derived components that may contain unknown pathogens, contaminants, or immunogenic substances. The chemically defined media use only synthetic or highly purified components with known safety profiles, removing the source of teratoma formation risk while preserving the ability to efficiently differentiate cells into pancreatic progenitors and endocrine cells.
3Adaptability or versatility
If current differentiation methods are used, then some cell lines can be differentiated, but adaptability to multiple cell lines deteriorates
Solution Approach 1:
The invention creates a universal differentiation protocol using chemically defined media that can be applied to multiple hPSC lines (including H9, H1, and various iPSC lines) with the same basic formulation. The media contain a core set of growth factors and inhibitors that work across different cell line backgrounds, making the protocol broadly applicable while maintaining controlled and reproducible conditions through chemical definition rather than cell-line-specific optimization.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.